Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $41.00 Price Target at Stifel Nicolaus

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target upped by Stifel Nicolaus from $40.00 to $41.00 in a report released on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Barclays increased their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Bank of America upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Citigroup upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Jefferies Financial Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Friday, June 28th. They set a “buy” rating and a $37.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.78.

Syndax Pharmaceuticals Stock Performance

SNDX stock opened at $19.89 on Monday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -6.18 and a beta of 0.91. The firm has a 50-day simple moving average of $19.34 and a two-hundred day simple moving average of $20.62. Syndax Pharmaceuticals has a one year low of $11.22 and a one year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million for the quarter. The business’s revenue was up 3499999990.0% on a year-over-year basis. During the same period last year, the firm posted ($0.64) earnings per share. As a group, equities analysts predict that Syndax Pharmaceuticals will post -3.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $27,000. nVerses Capital LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $33,000. Quarry LP grew its stake in shares of Syndax Pharmaceuticals by 75.0% during the 2nd quarter. Quarry LP now owns 6,125 shares of the company’s stock worth $126,000 after purchasing an additional 2,625 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in shares of Syndax Pharmaceuticals by 28.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after purchasing an additional 1,587 shares during the period. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Syndax Pharmaceuticals by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).